Claims for Patent: 7,645,595

Summary for Patent: 7,645,595

Title:	Method of production of artificial skin
Abstract:	A method for production of artificial skin by administering matrix metalloproteinase inhibitor or matrix metalloproteinase inhibitor and matrix protein production promoting agent. The matrix metalloproteinase inhibitor is N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](3-picolyl)amino]-3-methylbuta- namide hydrochloride.
Inventor(s):	Amano; Satoshi (Yokohama, JP), Matsunaga; Yukiko (Yokohama, JP), Inomata; Shinji (Yokohama, JP)
Assignee:	Shiseido Company, Ltd. (Chuo-ku, Tokyo, JP)
Application Number:	12/059,935
Patent Claims:	1. A method for producing artificial skin, the method comprising: (a) forming a collagen gel layer containing human fibroblasts; (b) culturing epidermal keratinocytes on the collagen gel layer so the keratinocytes adhere to the gel layer to form an epidermal layer; and (c) continuing the culturing in an artificial skin forming medium comprising a matrix metalloprotease inhibitor, while exposing the epidermal layer to air, wherein the matrix metalloprotease inhibitor is gelatinase inhibitor, collagenase inhibitor, stromelysin inhibitor or matrilysin inhibitor. 2. The method of claim 1, wherein the matrix metalloprotease inhibitor is CGS27023A (N-hydroxy-2-[[(4-methoxyphenyl)sulphonyl]3-pycolyl)-amino]-3-m- ethylbutaneamide hydrochloride) or MMP-inhibitor (p-NH.sub.2-Bz-Gly-Pro-D-Leu-Ala-NHOH)(FN-437). 3. A method for producing artificial skin, the method comprising: (a) forming a collagen gel layer containing human fibroblasts; (b) culturing epidermal keratinocytes on the collagen gel layer so the keratinocytes adhere to the gel layer to form an epidermal layer; and (c) continuing the culturing in an artificial skin forming medium comprising a matrix metalloprotease inhibitor and a matrix protein producing promoting agent, while exposing the epidermal layer to air, wherein the matrix metalloprotease inhibitor is gelatinase inhibitor, collagenase inhibitor, stromelysin inhibitor or matrilysin inhibitor, and wherein the matrix protein production promoting agent is soy bean lysolecithin, transforming growth factor .alpha. (TGFa), transforming growth factor .beta.1 (TGFb1), transforming growth factor .beta.2 (TGFb2), transforming growth factor .beta.3 (TGFb3) or epithelial growth factor (EGF). 4. The method of claim 3, wherein the matrix metalloprotease inhibitor is CGS27023A (N-hydroxy-2-[[(4-methoxyphenyl)sulphonyl]3-pycolyl)-amino]-3-m- ethylbutaneamide hydrochloride) or MMP-inhibitor (p-NH.sub.2-Bz-Gly-Pro-D-Leu-Ala-NHOH)(FN-437).

Details for Patent 7,645,595

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2020-03-27